Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Why don't we initiate more large simple randomized controlled trials?

× No keyword cloud information.

10 in total

1. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

Authors: Peter Jüni; Anne W S Rutjes; Paul A Dieppe
Journal: BMJ Date: 2002-06-01

2. Initial patterns of use of COX-2 inhibitors by elderly patients in Ontario: findings and implications.

Authors: Muhammad Mamdani; Paula Rochon; Andreas Laupacis; Geoffrey Anderson
Journal: CMAJ Date: 2002-11-12 Impact factor: 8.262

3. Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach.

Authors: Andreas Laupacis; J Michael Paterson; Muhammad Mamdani; Alaa Rostom; Geoffrey M Anderson
Journal: CMAJ Date: 2003-11-25 Impact factor: 8.262

4. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors:
Journal: JAMA Date: 2002-12-18 Impact factor: 56.272

5. Why do we need some large, simple randomized trials?

Authors: S Yusuf; R Collins; R Peto
Journal: Stat Med Date: 1984 Oct-Dec Impact factor: 2.373

6. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors: F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal: JAMA Date: 2000-09-13 Impact factor: 56.272

Review 7. The double-edged sword of COX-2 selective NSAIDs.

Authors: James M Wright
Journal: CMAJ Date: 2002-11-12 Impact factor: 8.262

8. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors: C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal: N Engl J Med Date: 2000-11-23 Impact factor: 91.245

9. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.

Authors: Muhammad Mamdani; Paula A Rochon; David N Juurlink; Alex Kopp; Geoffrey M Anderson; Gary Naglie; Peter C Austin; Andreas Laupacis
Journal: BMJ Date: 2002-09-21

10. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors: Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal: JAMA Date: 2002-07-17 Impact factor: 56.272

10 in total

3 in total

Why don't we initiate more large simple randomized controlled trials?